期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

醋酸阿比特龙的合成 被引量：5

Synthesis of Abiraterone Acetate
下载PDF
导出
摘要 以去氢表雄酮为原料,经与水合肼缩合、碘代、再与3-吡啶溴化镁发生偶联反应、乙酰化等4步反应合成了目标产物醋酸阿比特龙,总收率为51.4%。产物结构经1 HNMR、元素分析表征。 Abiraterone acetate was synthesized from dehydroepiandrosterone by condensation with hydrazine,iodization,cross-coupling with 3-pyridylmagnesium bromide and acetylation in turn.The overall yield was51.4%.The structure of the compounds were determined by 1 HNMR and elemental analysis.
作者 丁亚明 顾晓波
机构地区 无锡卫生高等职业技术学校 江苏省原子医学研究所卫生部核医学重点实验室江苏省分子核医学重点实验室
出处 《化学与生物工程》 CAS 2014年第9期39-41,共3页 Chemistry & Bioengineering
关键词 去氢表雄酮 醋酸阿比特龙 合成 dehydroepiandrosterone abiraterone acetate synthesis
分类号 O626.32 [理学—有机化学] R914.5 [医药卫生—药物化学]
  • 相关文献

参考文献9

  • 1HIGANO C S. New treatment options for patients with metastatic castration-resistant prostate cancer[J]. Cancer Treat Rev, 2012, 38(5) :340-345.
  • 2BEDOYA D J, MITSIADES N. Abiraterone acetate, a first in-class CYP17 inhibitor,establishes a new treatment paradigm in castra- tion-resistant prostate cancer[J]. Expert Rev Anticanc Ther, 2011,12(1),1-3.
  • 3PEZARO C J, MUKHERJI D, BONO J S D. Abiraterone acetate: Redefining hormone treatment for advanced prostatecancer[J]. Drug Discov Today,2012,17(5-6) :221-226.
  • 4POTTER G A,BARRIE S E,JARMAN M,et al. Novel steroidal inhibitors of human cytochrome P45017e( 17a-hydroxylase-C17, 20-1yase) :Potential agents for the treatment of prostatic cancer [J]. J Med Chem,1995,38(13) :2463-2471.
  • 5BARRLE S E,JARMAN M,POTTER G A. 17-Substituted ster- oids useful in cancer treatment:GB,2265624[P]. 1993-06-10.
  • 6POTTER G A, HARDCACSTLE I R. Synthesis of 17-(3-pyridyl) steroids:GB, 2282377 A[P]. 1995-05-04.
  • 7POTTER G A, HARDCASTLE I R,JARMAN M. A convenient, large-scale synthesis of abiraterone acetate[β-aeetoxy-17-(3-pyri- dyl) androsta-5,16-alien], a potential new drug for the treatment of prostate cancer[J]. Org Prep Proced Int,1997,29(1) :123-134.
  • 8王红波,杨银萍,赵桂芳,唐云峰,赵志全.醋酸阿比特龙的合成[J].中国医药工业杂志,2012,43(10):804-806. 被引量：8
  • 9安迪,李洪玉,李金岭,姜申德.阿比特龙醋酸酯的合成[J].化学试剂,2013,35(2):124-126. 被引量：4

二级参考文献16

  • 1邢念增,王国栋.晚期前列腺癌治疗的新靶点[J].中华临床医师杂志（电子版）,2011,5(18):5253-5255. 被引量：6
  • 2Rajfer J, Sikka SC, Rivera F, et al. Mechanism of inhibition of human testicular steroidogenesis by oral ketoconazole EJ]. J Clin Endocrinol Metab, 1986, 63:1193-1198.
  • 3Potter GA, Barrie SE, Jarman M, et al, Novel steroidal inhibitors of human cytochrome P45017ct (17ct-hydroxylase- C17,20-1yase) : potential agents for the treatment of prostatic cancer [J]. JMedChem, 1995, 38(13) : 2463-2471.
  • 4Potter GA, Hardcastle IR. Synthesis of 17-(3-pyridyl)- steroids: WO, 9509178 [P]. 1995-04-06. (CA 1995, 123: 112515).
  • 5Nadia MS, Monika E, Stanley MR, et al. Some regioselective cross-coupling reactions of halopyridines and halopyrimidines [J]..1 Chem Soc Perkin Trans I, 2002, 16: 1847-1849.
  • 6US. FDA approves Zytiga for late-stage prostate cancer[EB/OL].http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm253055.htm,2011.
  • 7ATTARD G,REID A H M,A' HERN R. Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer[J].Journal of Clinical Oncology,2009,(23):3742-3748.
  • 8ATTARD G,DE BONO J S. Translating scientific advancement into clinical benefit for castration-resistant prostate cancer patients[J].Clinical Cancer Research,2011.3867-3875.
  • 9DE BONO J S,LOGOTHETIS C J,MOLINA A. Abiraterone and increased survival in metastatic prostate cancer[J].New England Journal of Medicine,2011,(21):1995-2005.
  • 10BARRLE S E,JARMAN M,POTTER G A. 17-Substituted steroids useful in cancer treatment[P].GB,2 265 624,1993.

共引文献9

同被引文献22

引证文献5

二级引证文献7

化学与生物工程
2014年 第9期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部